CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 18 enrolled
Drug / intervention
Maraviroc +3 moredrug
Likely dose
Maraviroc 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00853840
NCT00853840Phase 4Completed
CompareCT.gov

A Randomized, Single-Blinded, Placebo-Controlled Two-Way Crossover Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

ViiV Healthcare·interventional·Posted Mar 2, 2009·Updated Jan 25, 2013

In Brief

A Phase 4 clinical trial evaluating Maraviroc, Vardenafil, and 1 other intervention for AIDS. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in subjects receiving a single dose of vardenafil.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAIDS
CountriesBelgium
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2, 2009
Enrollment StartApr 1, 2008
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.3 years ago

Interventions

Maravirocdrug

Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.

Vardenafildrug

Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.

Maravirocdrug

Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.

Placebodrug

Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.